Targets › PAP
1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.
Polymerase that creates the 3'-poly(A) tail of mRNA's. Also required for the endoribonucleolytic cleavage reaction at some polyadenylation sites. (UniProt, P51003)
Open in Phaseline: the race on PAP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Wisconsin, Madison | pTVG-HP Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) | PAP | Phase 2 | Castration-resistant Prostate Cancer; Prostate Cancer; Prostate Cancer Patients | Mar 2027 |
Castration-resistant Prostate Cancer (1) Prostate Cancer (1) Prostate Cancer Patients (1)
mixed (1)
University of Wisconsin, Madison (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.